A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2018
At a glance
- Drugs GSK 1437173A (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Herpes zoster
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline Biologicals
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 Planned End Date changed from 26 Nov 2019 to 5 Feb 2020.
- 26 Mar 2018 Planned primary completion date changed from 16 Feb 2019 to 15 Mar 2019.